Sun Pharma gains 3%; hits new high on UBS 'Buy' rating, sees more upside

UBS has a target price of Rs 2,450 on Sun Pharma and expects it to record the highest growth in the near-term and the medium-term via a ramp-up of the specialty drug pipelline.